The second presentation is on an oral tyrosine kinase 2 (TYK2) inhibitor for plaque psoriasis from InventisBio, which “really raised people’s eyebrows,” Gelfand said. In a phase 2 trial ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Late-breaking data supported the efficacy of icotrokinra, an interleukin-23 inhibitor, for plaque psoriasis. By week 24, 46% of icotrokinra-treated patients achieved IGA 0 and 40% reached PASI 100.

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

Certain medications may worsen psoriasis so it is always important to consult your provider before taking a new medicine.